NasdaqGM:ARDXBiotechs
How Investors Are Reacting To Ardelyx (ARDX) Hedge Fund Buying Despite Medicare Setback
In recent months, Ardelyx has drawn attention as Wall Street forecasts a shift from losses to profits, supported by strong Ibsrela prescription growth and long-dated patents, even as the company lost its appeal for separate Medicare payments on dialysis drug Xphozah.
An interesting angle is that hedge funds have been increasing their positions in Ardelyx despite the Medicare setback, suggesting institutional investors remain focused on the company’s earnings turnaround potential and...